Immune-mediated inflammatory diseases (IMIDs) represent a major global health issue with an incidence in Western society that approximates 5-7%. They are characterized by chronic inflammation, and corticoids or non-steroidal anti-inflammatory drugs (NSAIDs) are usually prescribed to regulate inflammatory response. Related severe side effects foster continue drug development that also focus on the regulation of signaling pathways of inflammatory cytokines with the recent use of cytokine-targeted monoclonal antibodies. However, these therapies could trigger the development of opportunistic diseases and patients might become refractory to these treatments. During the last decades, scientists draw their attention to the metal-control immunology, an interesting strategy in the drug development including chelators of metal ions as the deferoxamine. Natural products (NPs) are a source of innovative drugs and includes bioactive marine NPs (MNPs). Some MNPs isolated from marine microorganisms showed anti-inflammatory bioactivities including exopolysaccharides (EPS) that exert immunomodulatory activities. Considering the originality and the diversity of MNPs produced by New Caledonian marine microorganisms, we investigated the potential immunomodulatory activity of EPS from local marine bacteria. These EPS are available from the collection of the New Caledonian startup BIOTECAL. In vitro model of PMA-differentiated THP-1 macrophage was used to study the anti-inflammatory effect of 10 EPS. Cells were induced with LPS (1 µg/mL) with or without EPS at 250 ng/mL. The cytotoxicity was evaluated by quantifying the LDH released in the culture supernatant and confirmed no cytotoxicity for the EPS at the concentration tested. The production of cytokines was quantified by ELISA and the EPSs were shown to inhibit the release of inflammatory cytokines TNF-α and IL-6. A dose effect response for one of the most active EPS (BT17) was evaluated. The potential of chelating metal ions was evaluated by FTIR and SEM techniques for BT17. This work aimed at valorizing MNPs from New Caledonian marine biodiversity, answering on the one hand ongoing research in drug discovery. On the other hand, it responds to the local and national strategies for sustainable economic development based on biosourcing and blue technology.